alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 351–375 of 442 studies · free to read · tagged Prevention (page 15 of 18) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of these 442 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Insights for dementia risk reduction among lower SES adults in OECD countries: scoping review of interventions targeting multiple common health risk factors

✓ Peer-reviewed alzhub usefulness score 42 out of 100. International Journal for Equity in Health 2025-02-24

The number of people living with dementia is expected to rise to 153 million cases globally by 2050. 4 key findings →

Participants: 17,500 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Investigating Modifiable Factors Associated with Cognitive Decline: Insights from the UK Biobank

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Biomedicines 2025-02-21

Our findings revealed a significant impact of unfavorable medical and psychiatric histories on processing speed and visual episodic memory decline (Hazard Ratio (HR) = 1.34, 95% CI: 1.20–1.51, p = 6.06 × 10⁻7; HR = 1.50, 95% CI: 1.22–1.86, p = 1.62 × 10⁻4, respectively). 4 key findings →

Participants: 453,950 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neuromolecular medicine 2003-01-01

Studies of amyloid precursor protein transgenic mice suggest that immune responses to amyloid beta peptide (Abeta) may be instrumental in the removal of plaques from the brain, but the initial clinical trial of an Abeta vaccine in patients with Alzheimer s disease (AD) was halted as the result of serious neurological complications in some patients. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Potential role of dietary n-3 fatty acids in the prevention of dementia and macular degeneration

✓ Peer-reviewed alzhub usefulness score 41 out of 100. The American journal of clinical nutrition 2006-06-01

Dementia and age-related macular degeneration (AMD) are major causes of disability in the elderly. n-3 Fatty acids, particularly docosahexaenoic acid (DHA), are highly concentrated in brain and retinal tissue and may prevent or delay the progression of dementia and AMD. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Age-related hearing loss and dementia risk across the lifespan: mechanisms, equity, and prevention

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neuroscience 2025-08-28

Age-related hearing loss (ARHL) has emerged as a significant and potentially modifiable risk factor for neurodegenerative disorders, including Alzheimer's disease. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Climate Change and Health Within the Sendai Framework for Disaster Risk Reduction: Opportunities and Challenges

✓ Peer-reviewed alzhub usefulness score 41 out of 100. International Journal of Disaster Risk Science 2025-01-07

The Sendai Framework for Disaster Risk Reduction 2015–2030 (SFDRR) is at its 10th anniversary amidst a rapidly changing climate, which, together with social vulnerabilities, have led to significant impacts on human health and well-being. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Clinical Medicine 2025-01-20

Statins show mixed results in CKD and ESRD, with limited benefits in reducing cardiovascular events in dialysis patients. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dementia in Sub-Saharan Africa: Risk factors, public perception, and management approaches

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Medicine Surgery and Public Health 2025-06-09

Dementia is becoming a major public health problem in Sub-Saharan Africa (SSA), with prevalence increasing due to demographic transitions, increasing life expectancy, and increasing prevalence of non-communicable diseases. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diet and Prevention of Cardiovascular Disease and Cancer

✓ Peer-reviewed alzhub usefulness score 41 out of 100. JACC CardioOncology 2025-08-29

Cardiovascular disease (CVD) and cancer remain the leading causes of mortality in the United States, where poor diet has surpassed smoking as the leading risk factor for death, and life expectancy has hit a plateau as CVD mortality has stagnated over the past decade. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Urban Planning for Disaster Risk Reduction and Climate Change Adaptation: A Review at the Crossroads of Research and Practice

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Sustainability 2025-10-14

This review seeks to understand what urban planning and management can do to reduce disaster risk and help cities adapt to the impacts of climate change. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Chronic caffeine consumption prevents obesity-induced cognitive and memory impairments by reducing neuroinflammation and enhancing neuronal activity in the hippocampus

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Pharmacological Research 2026-02-13

Obesity and its associated metabolic disturbances increase the risk of cognitive decline, dementia, and anxiety-related disorders. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The cost of a Mediterranean Diet and walking intervention to reduce risk of dementia and improve quality of life in independent living populations in Australia: The MedWalk randomised controlled trial

✓ Peer-reviewed alzhub usefulness score 41 out of 100. British Journal Of Nutrition 2025-10-17

Change in QoL (decreased, maintained or improved) was determined using a cross-tabulation test. 4 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

From dementia prevention research to global FINGER-based multi-domain interventions and implementation strategies

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cerebral Circulation - Cognition and Behavior 2025-01-01

The demographic transition during the recent decades has resulted in an increase in older adults globally. 2 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impact of annual wellness visits on preventing falls and fractures for Alzheimer’s disease and related dementias older adults

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Age and Ageing 2026-03-01

AWVs were associated with reduced risks for falls (HR: 0.976 for 2 AWVs; 0.936 for ≥3 AWVs) and fractures (HR: 0.978 for 1 AWV; 0.960 for 2 AWVs; 0.927 for ≥3 AWVs), with greater reductions observed with more AVWs. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Neighborhood deprivation and midlife cognition: Evidence of a modifiable vascular pathway involving health behaviors and cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s & Dementia 2025-11-01

Neighborhood deprivation was associated with poorer cognition (r = 0.36, p < 0.001), greater prevalence of modifiable risk factors (r = 0.36, p < 0.001), and greater SVD burden (β = 0.18, p = 0.008). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lifestyle interventions for dementia risk reduction: A review on the role of physical activity and diet in Western and Asian Countries

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-01-23

Dementia, is a critical global public health challenge with no effective pharmacological treatments. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Intrinsic factors associated with engagement in healthy lifestyle behaviors for dementia risk reduction in midlife

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia Behavior & Socioeconomics of Aging 2025-04-06

LPA identified four intrinsic profiles: Profile 1 had low motivation; Profile 2 had high motivation and self-efficacy, but poor dementia knowledge; Profile 3 had moderate motivation; and Profile 4 had low motivation and high apathy. 5 key findings →

Participants: 347 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Integrative Strategies for Preventing and Managing Metabolic Syndrome: The Impact of Exercise and Diet on Oxidative Stress Reduction—A Review

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Life 2025-05-08

Metabolic syndrome (MetS) is characterized by central obesity, insulin resistance, hypertension, dyslipidemia, and chronic inflammation, significantly increasing the risk of cardiovascular disease and type 2 diabetes. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lessons from the Implementation of the Sendai Framework for Disaster Risk Reduction from Latin America and the Caribbean

✓ Peer-reviewed alzhub usefulness score 40 out of 100. International Journal of Disaster Risk Science 2025-01-21

Over the past decade, Latin America and the Caribbean (LAC) have made progress in implementing the Sendai Framework for Disaster Risk Reduction 2015–2030 (SFDRR). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events